Allianz Asset Management Gmb H Coherus Bio Sciences, Inc. Transaction History

Allianz Asset Management Gmb H

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$3.79 - $8.3 $820,914 - $1.8 Million	216,600 New	216,600 $924,000
Q2 2021 Aug 16, 2021	SELL	$12.95 - $15.41 $2.2 Million - $2.62 Million	-170,168 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$14.42 - $21.39 $929,412 - $1.38 Million	64,453 Added 60.97%	170,168 $2.49 Million
Q3 2020 Nov 13, 2020	SELL	$17.41 - $19.89 $251,121 - $286,893	-14,424 Reduced 12.01%	105,715 $1.94 Million
Q2 2020 Aug 14, 2020	BUY	$14.43 - $19.16 $1.45 Million - $1.93 Million	100,479 Added 511.08%	120,139 $2.15 Million
Q1 2020 May 14, 2020	SELL	$11.67 - $22.53 $110,316 - $212,976	-9,453 Reduced 32.47%	19,660 $318,000
Q4 2019 Feb 13, 2020	SELL	$16.33 - $21.37 $2,237 - $2,927	-137 Reduced 0.47%	29,113 $525,000
Q3 2019 Nov 13, 2019	BUY	$16.3 - $23.37 $476,775 - $683,572	29,250 New	29,250 $592,000
Q2 2017 Aug 14, 2017	SELL	N/A	-189,745 Closed	0 $0
Q1 2017 Apr 17, 2019	BUY	N/A	27,140 Added 16.69%	189,745 $3.98 Million
Q4 2016 Apr 17, 2019	BUY	N/A	20,300 Added 14.27%	162,605 $4.58 Million
Q3 2016 Apr 17, 2019	BUY	N/A	142,305	142,305 $3.74 Million

135

77.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $122M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Allianz Asset Management Gmb H with notifications on news.